International Journal of Cancer and Biomedical Research最新文献

{"title":"Significance of CD200 expression in patients with acute myeloid leukemia and its correlation with other prognostic markers","authors":"A. Rabea, Hala M. Farawela, R. Soliman, N. Hassan, Reem Nabil, M. Fouad","doi":"10.21608/jcbr.2022.118363.1247","DOIUrl":"https://doi.org/10.21608/jcbr.2022.118363.1247","url":null,"abstract":"Background and Objectives : Acute myeloid leukemia (AML) known as cancer of blood and bone marrow is regarded as the commonest acute leukemia in adult patients. characterized by uncontrolled proliferation of hematopoietic progenitor cells with arrest of maturation and disruption of normal hematopoiesis. CD200 is a protein belonging to the immunoglobulin superfamily, it has an immunosuppressant effect by interacting with its receptor (CD200R). Aim: The main aim of this study is to investigate the expression of CD200 on leukemic myeloid cells. Various molecular prognostic markers and other clinical and laboratory findings were studied in relation to CD200 expression. Patients and Methods : The present study was conducted on newly diagnosed AML patients attending the adult Hematology/Oncology Clinic of the National Cancer Institute. The expression of CD200 was determined by flow cytometry using anti-CD200 monoclonal antibodies. CD200 expression considered positive if ≥20% and negative if <20%. Results : CD200 positive expression was found in 62/104 (59.5%) patients, CD200 was more expressed in CD34 positive cases (P= 0.012) and cases with gum hyperplasia (P= 0.046). FLT3/ITD mutation and NPM mutation were less detected in AML patients with positive CD200 (p=0.045 and p= 0.036 respectively). We found a statistically significant relation between inv16 and CD200 positive expression (p=0.005). Conclusion : CD200 could be used as a biological biomarker in AML pathophysiology, and could be incorporated in the initial diagnostic workup in patients treated within clinical trials for the discovery of new therapy which target malignant leukemic cells without harming other cells in AML.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130039712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gene-behavior theory: Behavior from nil to tangible glycosylation-implications for cancer prognosis and treatment strategies","authors":"S. Mohamed","doi":"10.21608/jcbr.2022.98310.1234","DOIUrl":"https://doi.org/10.21608/jcbr.2022.98310.1234","url":null,"abstract":"Increased disease susceptibility in some communities is problematic for health planners and providers. The previous gene-behavior theory outlined a causal relationship between behavior and disease susceptibility in non-coding satellite DNA. While this theoretical viewpoint requires further thought to know more about this relationship; it does provide a platform for further rigorous research. In this review, glycosylation was reviewed from a new perspective, thus we focused and tracked its association with satellite DNA and cancer susceptibility using sequential reasoning. Our model suggests glycosylation is a major tangible action of satellite DNA alterations caused by behaviors. Our model also suggests glycosylation is influenced by genetic anticipation. In addition, glycosylation patterns may function as behavioral biomarkers for the social sciences, community-targeted approaches, and early prognostic tools for behavioral-related pathogenesis. These notions open up new avenues for behavioral immunogenetics and behavioral epidemiology areas. Therefore, more in-depth and improved treatment strategies are required, especially for cancer.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130413552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting causes of death among vulvar cancer patients; SEER database analysis","authors":"Mohamed Hafez, G. Tawfik, Reem Yousef, S. Antar, Ahmed Nazzal, M. Hosh, Mahmoud Warda, Richard Leu, B. Refky","doi":"10.21608/jcbr.2022.115165.1242","DOIUrl":"https://doi.org/10.21608/jcbr.2022.115165.1242","url":null,"abstract":"Background: This study aims to identify causes of death among vulvar cancer patients diagnosed in the period between 2004 and 2013, using the Surveillance, Epidemiology, and End-Results (SEER) Program. Patients Methods: Data of 3769 Women with vulvar cancer, aged 40 years or more were extracted. Causes of death were categorized into vulvar cancer death, other cancer death, and other causes of death. The statistical analysis was performed using R (Version 3.4.0) utilizing the survival package (Version 2.41-3) and competing for the risk package. Results: At the end of the follow-up period, 2520 patients (66.9%) were alive while 1249 patients (33.14%) were dead. Of the 1249 deaths, 632 (50.6%) were attributed to vulvar cancer, 184 (14.7%) to other cancers, and 433 (34.66%) to other causes of death. Cardiovascular diseases and other gynecological cancers were the most common causes of death after vulvar cancer representing 16.65% and 5.28% of all deaths respectively. Advanced disease stage and more than three positive lymph nodes were associated with an increased risk of death due to other cancers. Simple and total surgeries were associated with lower risk. Non-cancer-related deaths were higher in unmarried women or in those who underwent surgical treatment. Conclusions: Non-cancer causes in addition to cancers other than vulvar cancer account for half of all deaths that occurred among patients diagnosed with vulvar cancer. Cardiovascular diseases and other gynecologic cancers are the most significant causes of death after vulvar cancer.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129562678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RRBP1 Expression in wild and mutated p53 immunophenotype endometrioid endometrial carcinoma: Relation to ER-α and clinicopathologic factors","authors":"M. Ali","doi":"10.21608/jcbr.2022.124769.1254","DOIUrl":"https://doi.org/10.21608/jcbr.2022.124769.1254","url":null,"abstract":"Background : Endometrial carcinoma (EC) is the most common gynecologic tumor in the developed world and in Egypt. Ribosome-binding protein 1 (RRBP1) is a membrane protein of rough endoplasmic reticulum essential for stabilization of endoplasmic reticulum. Overexpression of RRBP1 was detected in several malignant tumors. p53 is a tumor suppressor transcription factor encoded by TP53. The mutation of TP53 is considered the most common significant molecular alteration in half of human cancers. Aim : This study aimed to explore the immunohistochemical expression of RRBP1 in wild and mutated p53 immunophenotype endometrioid EC in relation to estrogen receptor alpha (ER-α) status and clinicopathological factors. Materials and Methods: Fifty-six endometrioid EC paraffin blocks were collected. Sections were stained with anti-RRBP1, anti-p53, and anti-ER-α antibodies. Results: RRBP1 overexpression was significantly related to high tumor grade, presence of lymphovascular invasion (LVI), advanced TNM staging, and negative ER-α. Mutated-type p53 expression was associated with high grade, LVI, advanced TNM staging, and negative ER-α. A Significant difference in p53 expression patterns was detected in relation to clinicopathological prognostic factors. Studied tumors with positive ER-α nuclear expression significantly showed wild-type p53 expression patterns more frequently compared to EEC with negative ER-α expression. Furthermore, a positive correlation was detected between RRBP1 overexpression and mutated-type p53. Conclusion : RRBP1 is considered a bad prognostic indicator in EEC and together with mutated p53 expression could be beneficial as a potential therapeutic target for EC.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117152683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethylenediamine tetra acetic acid (EDTA) enhances the antitumor efficacy of cisplatin against human breast cancer cells in vitro","authors":"S. El-Naggar, Y. El-Bolkiny, Fatheya Ibrahim","doi":"10.21608/jcbr.2022.96763.1233","DOIUrl":"https://doi.org/10.21608/jcbr.2022.96763.1233","url":null,"abstract":"Background: Ethylenediamine tetra acetic acid (EDTA) is used in several biomedical applications. Aim : The aim of this study was to investigate the effect of EDTA treatment on anticancer efficacy of cisplatin (Cis) against human breast cancer (MCF-7) cells in vitro . Materials and Methods: MCF-7 cells were treated either with Cis, EDTA, or their combination for 24h in vitro . The percentages (%) of the inhibitory, and the median inhibitory concentration (IC 50 ) of EDTA were determined by MTT assay. The % of Cis and EDTA on early and late apoptosis, necrosis, and cell cycle of MCF-7 were assessed by flow cytometry. Results: Our data showed slight antitumor effects for EDTA in vitro . However, Cis/EDTA treatment increased the antitumor efficacy of Cis as evidenced by increasing IC 50 , and the percentage of MCF-7 mortality. Cis/EDTA co-treatment also increased the % of apoptotic and necrotic MCF-7 cells post 24 h of treatment (26.57 and 16.28%, respectively). Furthermore, this co-treatment arrested MCF-7 cell cycle at G 0 phase (32.8%) and G 2 /M phase (30.25%). Conclusion: Co-treatment of EDTA with Cis increased the anticancer efficacy of Cis.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"87 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123184417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The validity of giving adjuvant capecitabine after standard anthracycline and/or taxanes based neo-/adjuvant chemotherapy in early triple-negative breast cancer patients: An Egyptian prospective multicentric phase III trial","authors":"L. Abdelaziz., A. Hefni, A. Attia, loay Gertalla, Marwa I Abdelgawad","doi":"10.21608/jcbr.2022.125666.1255","DOIUrl":"https://doi.org/10.21608/jcbr.2022.125666.1255","url":null,"abstract":"Background : Triple-negative breast cancer (TNBC) is considered an aggressive breast cancer subtype despite giving standard therapies, these patients have high metastatic and relapse rates in addition to short survival. Therefore, we conducted this trial to study the validity of giving adjuvant Capecitabine, after receiving standard neoadjuvant /adjuvant chemotherapy in operable TNBC patients. The primary end point was disease-free survival (DFS) and secondary end points were overall survival (OS) and safety profile. Material and Methods : The 89 eligible patients were randomly assigned into two groups (A “Capecitabine arm” and B “observation arm”) after receiving neo/adjuvant anthracycline and/or taxanes-containing chemotherapy. Results : 78.7% were invasive duct carcinoma (IDC), and a median age was 48 years. 50.6% were node positive patients. 79.5% received adjuvant anthracyclines and taxanes chemotherapy protocol for group A and (75.6%) for group B. (56.2%) underwent breast-conservative surgery. regarding 4-year disease free survival (DFS), there was statistically significant difference between both groups (P = 0.032) and 4-y overall survival (OS) (P = 0.050)) with an acceptable toxicity profile in the Capecitabine arm. Conclusions : Our study showed statistically significant increase in DFS and OS after giving adjuvant Capecitabine to standard Neo-/Adjuvant chemotherapy in early TNBC patients with acceptable toxicity of Capecitabine arm. However, a larger study with more number of patients is recommended to give more statistical powered results.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124171072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended oral care can prevent oral mucositis in immunocompromised acute lymphoblastic leukemia ghildren","authors":"Aya Gamal, S. Abd El Mabood, H. Shalan, A. Mansour","doi":"10.21608/jcbr.2021.93085.1228","DOIUrl":"https://doi.org/10.21608/jcbr.2021.93085.1228","url":null,"abstract":"Background : Oral mucositis is a serious complication of chemotherapy. The incidence of chemotherapy induced mucositis ranges from 40%-76% with many studies suggesting that children are more susceptible than adults. Aim: We aimed at evaluating pretreatment dental rehabilitation in protecting from oral mucositis in acute lymphoblastic leukemia children. Patients and Methods: An open labeled randomized controlled study including 50 newly diagnosed patients with dental caries was conducted. They were classified into a group (A) using standard oral care and group (B) undergoing extended oral care using dental rehabilitation by a pediatric dentist before induction chemotherapy. Results: No differences were observed between both groups regarding mucositis development or severity. Mucositis was more among patients with lower neutrophil count, platelet count and poor compliance to daily oral care (P value <0.001, 0.01 and <0.001) respectively. A positive correlation between mucositis grade and Decayed; Missing and Filled Teeth (DMFT) score and a negative correlation between mucositis grade and neutrophil count were noticed with statistical significance. Conclusion: Although dental rehabilitation before induction chemotherapy did not seem to reduce either the occurrence or grade of oral mucositis, the positive correlation between mucositis severity and DMF score supports the importance of pretreatment dental assessment and rehabilitation in such immunocompromised patients. Neutropenia, thrombocytopenia and poor oral care were found to be risk factors for oral mucositis.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125040814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perception and Experience of Oncologists regarding Vaccination of Cancer Patients on Active Treatment","authors":"Nervana Hussien, M. EzzEldin, A. Abdelaziz, Haitham M Ahmed, M. El kassas, I. Elzayat, W. Elkhatib, Soha Ahmed","doi":"10.21608/jcbr.2022.120116.1248","DOIUrl":"https://doi.org/10.21608/jcbr.2022.120116.1248","url":null,"abstract":"Background : The COVID-19 epidemic has wreaked havoc on individuals of all ages throughout the world. I In unprecedented time frame, its vaccination has been produced and made available to the general population. However, due to varying levels of its acceptance, vaccination did not gain widespread adoption. Aim: We aimed to measure the perception and experience of oncologists towards COVID-19 vaccination in cancer patients on active therapy. Methods: A cross-sectional survey with a self-administered questionnaire was circulated among oncology specialists in Egypt between September – and December 2021. Results: A total of 83 respondents participated of which 59% had more than 10 years of experience in the oncology field. The majority of the respondents 75 (90.4%) recommended giving the vaccine once available in case of hormonal treatment meanwhile the lowest percentage 32 (38.5%) was for anti CD20 monoclonal antibody, either as a single agent or combined with chemotherapy. Choices of 49 (59%), 46 (55%), and 43 (51.8%) to vaccinate patients on active treatment with cytotoxic chemotherapy, MoAb (except anti CD20), and immunotherapy respectively were reported. The inactivated COVID-19 virus vaccine was recommended by 39 (47%), followed by Vector vaccines in 20 (24.1%), 8 (9.6%) for the messenger RNA (mRNA) vaccines, while 16(19.3%) of them were undecided. Thirty-nine (47%) of the participants reported that patients on active treatment developed side effects from vaccination. The most conveyed side effects were fatigue in 34 (87%), fever or a local reaction each in 28 (71.8%), headache and myalgia equally in 19 (48.7%), and chills in 11 (28.2%), and myalgia in10 (25.6 %). Conclusion: Strategies to address the practicality of dealing with vaccination in cancer patients are needed. Emphasis on the installation of the latest data in caring for this population and increased awareness of the services provided is crucial. Surveys are a useful tool reflecting real-world practice.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133275160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutropenic Fever in Pediatric Patients with Cancer in South Egypt: A Report from a Single Institute","authors":"H. Sayed, Youstina Amir, A. Osman","doi":"10.21608/jcbr.2022.110606.1240","DOIUrl":"https://doi.org/10.21608/jcbr.2022.110606.1240","url":null,"abstract":"Background : Fever and neutropenia (FN) is a potentially life-threatening complication of chemotherapy in children with cancer. Aim: Our objectives were to describe the characteristics of episodes of FN experienced by our patients and evaluate their outcomes and factors affecting them. Material & Methods: A prospective observational study was conducted at Pediatric Oncology Department, South Egypt Cancer Institute, Assiut University. All pediatric patients ≤ 18 years with either hematological or solid tumors admitted with documented episodes of FN after receiving myelosuppressive chemotherapy were included in this study between February 2018 and February 2020. Results: 200 episodes of FN experienced by 125 pediatric cancer patients were included. The median age was six years; 60% of the patients were boys. FN was more prevalent among patients with hematological malignancies. Associated comorbidities were reported in 10.5%. Eighty percent of episodes were stratified as high-risk, with profound neutropenia reported in 47%. The focus of infection was documented in 82% of episodes. Blood-stream infections were 53.1% for Gram-negative and 24.4% for fungal isolates. Infection-related mortality was reported in 7% of episodes. Diagnosis, disease status, risk stratification, presence of comorbidity, and the grade of neutropenia significantly affected the outcome. Conclusion: Although satisfactory therapeutic interventions for neutropenic patients with fever, life-threatening resistant bacterial and fungal isolates were reported at high rates that mandate calling for an urgent review of infection control policy.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"70 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124282644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison between the risk of ipsilateral breast tumor recurrence after breast-conserving surgery in early breast cancer cases treated by whole breast irradiation with and without boost in patients ≥ 50 years old","authors":"H. Elkalla, Dalia Morad, Alyaa R. Elsergany, L. Abdelaziz.","doi":"10.21608/jcbr.2022.115902.1244","DOIUrl":"https://doi.org/10.21608/jcbr.2022.115902.1244","url":null,"abstract":"Background : Breast-conserving therapy (BCT) is the standard treatment for early breast cancer (BC). Radiotherapy after breast-conserving surgery (BCS) decreases the local recurrence and reduces mortality. Being young is documented as an important poor prognostic factor for disease control. Boost irradiation induces some pitfalls, including moderate to severe fibrosis, impaired cosmoses, and the higher cost of an additional boost therapy. Patient and Methods : It is a multicentric retrospective comparative study done at the Clinical Oncology and Nuclear Medicine Department, University Hospital and and unit at of Egypt from January 2016 to December 2017. We analyzed 120 cases of early BC patients with negative margins and low-grade tumors after BCS. They were treated with whole-breast irradiation (WBI) without (group A) and with (group B) boost. Results : The median follow-up was 44 months. The local recurrences occur only in 2 cases (3%) and 3 cases (5%) of groups A and B respectively (P = 0.6). Distant metastasis were found in 2 cases (3%) and 4 cases (7%) of group A and B respectively (P = 0.3). The mean overall survival (OS) was 52.8 and 53.2 months for groups A & B respectively (P = 0.6). The mean disease-free survival (DFS) was 54.6 and 52.1 months for groups A and B respectively (P = 0.3). Conclusion : We did not find any difference between boost and no boost radiotherapy after BCS in patients ≥50 years old with early BC regarding local failure, DFS and OS.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"12 9","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"113932745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}